crenolanib + mitoxantrone + cytarabine

Crenolanib + mitoxantrone + cytarabine is a combination regimen evaluated for **relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations**. Crenolanib is a potent, selective small-molecule inhibitor of class III receptor tyrosine kinases, particularly **FLT3** and **PDGFR** (platelet-derived growth factor receptor). Mitoxantrone is an anthracenedione antineoplastic agent that intercalates DNA and inhibits topoisomerase II, leading to DNA strand breaks. Cytarabine is a pyrimidine nucleoside analog that inhibits DNA synthesis during S-phase, resulting in apoptosis of rapidly dividing cells. The regimen is used as salvage therapy and under investigation for improving event-free and overall survival in FLT3-mutated AML[1][2][3]. This triple combination is usually administered intravenously, with crenolanib started after the initial chemotherapy phase as maintenance and in consolidation, sometimes alongside allogeneic hematopoietic cell transplantation.

Other names

crenolanib besylate + mitoxantrone + cytarabine